Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.

This marks Celltrion’s second regulatory submission for an omalizumab biosimilar as the US formulation patent protecting originator Xolair is set to expire late next year.

Pinotbio CEO Dooyoung Jung shares his views on the Korean ADC industry’s situation and efforts needed for the sector to grow, the strengths of his company's camptothecin-based platform and pipeline, and R&D and business strategies.

In a tough R&D environment, delivery technology-based new drug development activities by Korean firms are poised to remain robust in 2024.